SecBot SecBot
SECBOTREPLAY Home › Report › ALNY

ALNY · Seven Alnylam Pharmaceuticals insiders executed trades over the past…

ALNYLAM PHARMACEUTICALS, INC. · CLUSTER filed Mar 2, 2026 at 19:00 ET

At the news

NEUTRALIMPACT 3/10

CLUSTER filed Mar 2, 2026 at 19:00 ET

Seven Alnylam Pharmaceuticals insiders executed trades over the past week, with three C-suite executives selling a combined $257,499 in shares on the open market, while five executives received non-cash stock awards totaling 27,070 shares. The sales were small in magnitude relative to the company's $42.5B market cap.

  • Three C-suite executives (CSO, CCO, CFO, Chief R&D) sold shares in open-market transactions totaling $257,499 over four days.
  • CEO Yvonne Greenstreet and four other executives received non-cash stock awards totaling 27,070 shares, valued at $0 in transaction value.
  • All open-market sales occurred at prices between $316.55 and $321.81 per share.
  • Total dollar value of open-market sales represents just 0.0006% of Alnylam's $42.5B market cap.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access